Of note, the evidence for people with type 2 diabetes and CKD is more robust for SGLT-2 inhibitors, given that dedicated cardiorenal outcome trials have consistently demonstrated significant cardiorenal protection in this subpopulation. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.